

## Section cross-reference(s): 63

FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 5929066	A	19990727	US 1998-110511	19980706
	US 5789401	A	19980804	US 1997-908819	19970808
	WO 9907387	A1	19990218	WO 1998-US16103	19980731
	W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	AU 9887651	A1	19990301	AU 1998-87651	19980731
	EP 1001793	A1	20000524	EP 1998-939166	19980731
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
	BR 9811137	A	20000718	BR 1998-11137	19980731
	JP 2001513506	T2	20010904	JP 2000-506977	19980731
PRAI	US 1997-908819	A2	19970808		
	US 1998-110511	A	19980706		
	WO 1998-US16103	W	19980731		

AB A method is provided for treating Type II diabetes by administering to an affected individual a combination of chromic tripicolinate and biotin. The two compds. are administered orally or parenterally at daily dosages which provide between 50 and 1,000 .mu.g chromium and between 25 .mu.g

and

200 mg biotin, the amts. of chromium and biotin being selected together to

provide a greater than additive effect.

ST chromium biotin type II diabetes

IT Antidiabetic agents

Drug delivery systems

(chromium/biotin treatment of Type II diabetes)

IT Antidiabetic agents

Drug delivery systems

(oral; chromium/biotin treatment of Type II diabetes)

IT Drug delivery systems

(parenterals; chromium/biotin treatment of Type II diabetes)

IT Drug interactions

(synergistic; chromium/biotin treatment of Type II diabetes)

IT 50-99-7, D-Glucose, biological studies

RL: BPR (Biological process); BIOL (Biological study); PROC (Process)

(blood; chromium/biotin treatment of Type II diabetes)

IT **58-85-5, Biotin 14639-25-9**

RL: BAC (Biological activity or effector, except adverse); THU

(Therapeutic use); BIOL (Biological study); USES (Uses)

(chromium/biotin treatment of Type II diabetes)

IT 50-99-7, D-Glucose, biological studies

RL: BPR (Biological process); BIOL (Biological study); PROC (Process)

(chromium/biotin treatment of Type II diabetes)

RE.CNT 4

RE

(1) Anon; WO 9635421 1996 CAPLUS

(2) Boynton; US 5087623 1992 CAPLUS

(3) Evans; US 4315927 1982 CAPLUS

(4) McCarty; US 5789401 1998 CAPLUS

azt & cisplatin

L4 ANSWER 7 OF 11 CAPLUS COPYRIGHT 2001 ACS  
 AN 1999:468054 CAPLUS  
 DN 131:111435  
 TI Chromium/biotin treatment of Type II diabetes  
 IN McCarty, Mark F.  
 PA Nutrition 21, USA  
 SO U.S., 4 pp.  
 CODEN: USXXAM  
 DT Patent  
 LA English  
 IC ICM A61K031-555  
 ICS A61K031-415  
 NCL 514188000  
 CC 1-10 (Pharmacology)  
 Section cross-reference(s): 63

FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 5929066	A	19990727	US 1998-110511	19980706
	US 5789401	A	19980804	US 1997-908819	19970808
	WO 9907387	A1	19990218	WO 1998-US16103	19980731
	W:				
	AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE,				
	DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG,				
	KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX,				
	NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT,				
	UA, UG, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW:				
	GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES,				
	FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI,				
	CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	AU 9887651	A1	19990301	AU 1998-87651	19980731
	EP 1001793	A1	20000524	EP 1998-939166	19980731
	R:				
	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,				
	IE, FI				
	BR 9811137	A	20000718	BR 1998-11137	19980731
	JP 2001513506	T2	20010904	JP 2000-506977	19980731
PRAI	US 1997-908819	A2	19970808		
	US 1998-110511	A	19980706		
	WO 1998-US16103	W	19980731		
AB	A method is provided for treating Type II diabetes by administering to an affected individual a combination of <b>chromic</b>				

azt & cisplatin

AN 1999:565917 CAPLUS  
 DN 131:204609  
 TI Biochemical compositions containing hormones, amino acids, enzymes, vitamins, and minerals for the treatment of human diseases  
 IN Cochran, Timothy  
 PA USA  
 SO PCT Int. Appl., 54 pp.  
 CODEN: PIXXD2  
 DT Patent  
 LA English  
 IC ICM A61K031-56  
 ICS A61K031-595; A61K033-20; A61K033-26; A61K033-30; A61K033-32; A61K009-48  
 CC 63-6 (Pharmaceuticals)  
 Section cross-reference(s): 1

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9943329	A1	19990902	WO 1999-US4130	19990225
	W:	AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ,			
TM		RW:	GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG		
	US 6048846	A	20000411	US 1998-31227	19980226
	AU 9927901	A1	19990915	AU 1999-27901	19990225
PRAI	US 1998-31227		19980226		
	WO 1999-US4130		19990225		
AB	A compn. for treatment of a human body comprises a combination of at least one hormone, at least one amino acid, at least one enzyme and/or vitamin, and at least one mineral. The relative proportions of the hormone, amino acid, enzyme and mineral in the combination are balanced with respect to each other so as to be present in effective amts. to substantially restore to optimal levels in the body the hormone, amino acid, enzyme and mineral.				
	The hormone, amino acid, enzyme and mineral in the combination further operate synergistically to provide both nutrients and command/regulatory components to enable the body to effectively utilize the nutrients. The invention is also a method of forming a compn. for the treatment of a human body. Formulation of the invention compn. is disclosed. Efficacy of the formulation in treatment of a patient suffering from severe cardiovascular disease is reported.				
ST	biochem hormone amino acid enzyme vitamin; cardiovascular disease mineral hormone amino acid				
IT	Antianginal agents Antiarthritics Antidiabetic agents Antioxidants Drug delivery systems Nutrients (biochem. compns. contg. hormones, amino acids, enzymes, vitamins, and				

minerals for treatment of human diseases)

IT Carotenes, biological studies  
 Enzymes, biological studies  
 Hormones, animal, biological studies  
 Lecithins  
 Minerals, biological studies  
 Phosphatidylcholines, biological studies  
 Vitamins  
 RL: BAC (Biological activity or effector, except adverse); THU  
 (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (biochem. compns. contg. hormones, amino acids, enzymes, vitamins, and  
 minerals for treatment of human diseases)

IT Cardiovascular system  
 (disease; biochem. compns. contg. hormones, amino acids, enzymes,  
 vitamins, and minerals for treatment of human diseases)

IT Heart, disease  
 (failure; biochem. compns. contg. hormones, amino acids, enzymes,  
 vitamins, and minerals for treatment of human diseases)

IT 50-81-7, L-Ascorbic acid, biological studies 53-43-0,  
 Dehydroepiandrosterone 56-85-9, L-Glutamine, biological studies  
 57-10-3, Palmitic acid, biological studies 57-11-4, Octadecanoic acid,  
 biological studies **58-85-5**, Biotin 59-30-3, Folic acid,  
 biological studies 59-43-8, Vitamin b1, biological studies 59-67-6,  
 Niacin, biological studies 60-18-4, L-Tyrosine, biological studies  
 60-33-3, 9,12-Octadecadienoic acid (9Z,12Z)-, biological studies  
 62-49-7, Choline 67-97-0, Vitamin d3 68-19-9, Vitamin b12 70-18-8,  
 L-Glutathione, biological studies 70-26-8, Ornithine 73-31-4,  
 Melatonin 74-79-3, L-Arginine, biological studies 79-83-4, Vitamin b5  
 83-88-5, Vitamin b2, biological studies 87-89-8, Inositol 94-62-2,  
 Piperine 98-92-0, Vitamin b3 107-35-7, Taurine 112-80-1,  
 9-Octadecenoic acid (9Z)-, biological studies 127-40-2, Lutein  
 150-13-0, Paba 299-27-4, Potassium gluconate 303-98-0, Coenzyme q10  
 373-49-9, Palmitoleic acid 432-70-2, .alpha.-Carotene 472-93-5,  
 .gamma.-Carotene 502-65-8, Lycopene 506-26-3, .gamma.-Linolenic acid  
 541-15-1, L-Carnitine 1406-18-4, Vitamin e 6217-54-5, Docosahexaenoic  
 acid 6556-11-2, Inositol hexanicotinate 7235-40-7, .beta.-Carotene  
 7439-89-6, Iron, biological studies 7439-95-4, Magnesium, biological  
 studies 7440-47-3, Chromium, biological studies 7440-50-8, Copper,  
 biological studies 7440-66-6, Zinc, biological studies 7440-70-2,  
 Calcium, biological studies 7553-56-2, Iodine, biological studies  
 7782-49-2, Selenium, biological studies 8059-24-3, Vitamin b6  
 10417-94-4, Eicosapentaenoic acid 12001-79-5, Vitamin k  
**14639-25-9** 25779-79-7, n-Acetyl cystine  
 RL: BAC (Biological activity or effector, except adverse); THU  
 (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (biochem. compns. contg. hormones, amino acids, enzymes, vitamins, and  
 minerals for treatment of human diseases)

RE.CNT 2

RE

- (1) Craft; US 5883086 A 1999 CAPLUS
- (2) Majeed; US 5536506 A 1996 CAPLUS

L8 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2001 ACS  
 AN 1999:468054 CAPLUS  
 DN 131:111435  
 TI Chromium/biotin treatment of Type II diabetes  
 IN McCarty, Mark F.  
 PA Nutrition 21, USA  
 SO U.S., 4 pp.  
 CODEN: USXXAM  
 DT Patent  
 LA English  
 IC ICM A61K031-555  
 ICS A61K031-415  
 NCL 514188000  
 CC 1-10 (Pharmacology)